{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T00:05:39Z","timestamp":1793664339573,"version":"4.5.1"},"reference-count":14,"publisher":"Japanese Society of Internal Medicine","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2024,6,15]]},"DOI":"10.2169\/internalmedicine.2731-23","type":"journal-article","created":{"date-parts":[[2023,11,5]],"date-time":"2023-11-05T22:12:54Z","timestamp":1699222374000},"page":"1797-1800","source":"Crossref","is-referenced-by-count":5,"title":["&lt;i&gt;De novo&lt;\/i&gt; Hepatitis B Virus Reactivation during Treatment with an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in a Patient with Advanced Lung Cancer"],"prefix":"10.2169","volume":"63","author":[{"given":"Ryota","family":"Horibe","sequence":"first","affiliation":[{"name":"Department of Respiratory Medicine, NTT-East Corporation Sapporo Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motohiro","family":"Yokota","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, NTT-East Corporation Sapporo Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koujiro","family":"Uemura","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, NTT-East Corporation Sapporo Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Midori","family":"Hashimoto","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, NTT-East Corporation Sapporo Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Kawagishi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, NTT-East Corporation Sapporo Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaoru","family":"Nishiyama","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, NTT-East Corporation Sapporo Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71: 209-249, 2021.","DOI":"10.3322\/caac.21660"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. de Jong D, Das JP, Ma H, et al. Novel targets, novel treatments: the changing landscape of non-small cell lung cancer. Cancers (Basel) 15: 2855, 2023.","DOI":"10.3390\/cancers15102855"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Drafting Committee for Hepatitis Management Guidelines the Japan Society of Hepatology. Japan Society of Hepatology Guidelines for the Management of Hepatitis B Virus Infection: 2019 update. Hepatol Res 50: 892-923, 2020.","DOI":"10.1111\/hepr.13504"},{"key":"4","unstructured":"4. Midha A, Dearden S, McCormack R. EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII). Am J Cancer Res 5: 2892-2911, 2015."},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Soria JC, Ohe Y, Vansteenkiste J, et al.; FLAURA Investigators. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med 378: 113-125, 2018.","DOI":"10.1056\/NEJMoa1713137"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Lee PH, Huang YH, Hsu YW, et al. Reactivation of hepatitis B virus in lung cancer patients receiving tyrosine kinase inhibitor treatment. J Clin Med 12: 231, 2022.","DOI":"10.3390\/jcm12010231"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Yao ZH, Liao WY, Ho CC, et al. Incidence of hepatitis B reactivation during epidermal growth factor receptor tyrosine kinase inhibitor treatment in non-small-cell lung cancer patients. Eur J Cancer 117: 107-115, 2019.","DOI":"10.1016\/j.ejca.2019.05.032"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Sugimoto R, Furukawa M, Senju T, et al. Risk factors for <i>de novo<\/i> hepatitis B during solid cancer treatment. World J Clin Cases 8: 6264-6273, 2020.","DOI":"10.12998\/wjcc.v8.i24.6264"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Kotake T, Satake H, Okita Y, et al. Prevalence and risk factors of hepatitis B virus reactivation in patients with solid tumors with resolved HBV infection. Asia Pac J Clin Oncol 15: 63-68, 2019.","DOI":"10.1111\/ajco.13050"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Tien YC, Yen HH, Li CF, et al. Changes in hepatitis B virus surface antibody titer and risk of hepatitis B reactivation in HBsAg-negative\/HBcAb-positive patients undergoing biologic therapy for rheumatic diseases: a prospective cohort study. Arthritis Res Ther 20: 246, 2018.","DOI":"10.1186\/s13075-018-1748-z"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Nakao M, Nakayama N, Uchida Y, et al. Nationwide survey for acute liver failure and late-onset hepatic failure in Japan. J Gastroenterol 53: 752-769, 2018.","DOI":"10.1007\/s00535-017-1394-2"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Concha-Benavente F, Ferris RL. Oncogenic growth factor signaling mediating tumor escape from cellular immunity. Curr Opin Immunol 45: 52-59, 2017.","DOI":"10.1016\/j.coi.2017.01.004"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Zeboudj L, Ma\u00eetre M, Guyonnet L, et al. Selective EGF-receptor inhibition in CD4<sup>+<\/sup> T cells induces anergy and limits atherosclerosis. J Am Coll Cardiol 71: 160-172, 2018.","DOI":"10.1016\/j.jacc.2017.10.084"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Gan CJ, Li WF, Li CN, Li LL, Zhou WY, Peng XM. EGF receptor inhibitors comprehensively suppress hepatitis B virus by downregulation of STAT3 phosphorylation. Biochem Biophys Rep 22: 100763, 2020.","DOI":"10.1016\/j.bbrep.2020.100763"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/63\/12\/63_2731-23\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T03:30:11Z","timestamp":1718422211000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/63\/12\/63_2731-23\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,15]]},"references-count":14,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.2731-23","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,15]]},"article-number":"2731-23"}}